Treatment to preserve the voice box in advanced throat cancer
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This study tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy before surgery. The goal is to shrink the tumor enough to save the voice box (larynx), instead of removing it. It is for people with advanced throat cancer that can be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have throat cancer that can be surgically removed but is locally advanced (stage T2-4a, N0-N3, no spread to other organs).
- You are between 18 and 70 years old.
- You are generally healthy enough to carry out daily activities (ECOG 0-1).
- You have not had anti-cancer treatment (like chemo, radiation, or surgery) in the past 6 months.
- You do not have other active cancers, severe autoimmune diseases, or uncontrolled infections.
- You are able to practice effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach to treat advanced larynx or hypopharynx cancer without removing the voice box. First, you get targeted radiation (SBRT), then a combination of chemotherapy and an immunotherapy drug called Toripalimab, which helps your immune system fight the cancer.
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy before surgery improves outcomes for people with advanced laryngeal or hypopharyngeal cancer. The treatment is given before your planned total laryngectomy, and the goal is to shrink the tumor and potentially improve long-term results.
This trial tests a new approach to treat throat cancer while trying to preserve your larynx (voice box). It combines chemotherapy drugs and an immunotherapy drug before surgery or radiation. The goal is to see if this can help you avoid needing to have your larynx removed.
This trial tests whether adding immunotherapy before surgery, followed by either radiation or organ-preserving surgery, can improve outcomes for people with locally advanced laryngeal or hypopharyngeal cancer. It may help avoid complete removal of the voice box.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
This trial tests whether giving a combination of an immunotherapy drug (PD-1 inhibitor) and chemotherapy before surgery can help treat advanced throat cancer. The goal is to see if this approach shrinks tumors and improves outcomes.
Hear when a new Laryngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.